LENSAR, INC.
| Revenue | $60.3M |
|---|---|
| Operating income | $4.4M |
| Net income | $19.9M |
| Free cash flow | $-4.4M |
| Operating margin | 7.3% |
| Net margin | 33.0% |
| Return on equity | 69.3% |
| Period | TTM 2026-06-30 |
OpenFilings analyst
Our analyst
Agentic read of the latest earnings call — recommendation updates when we process a new transcript. Research synthesis, not investment advice.
Cautiously constructive, but not yet a high-conviction buy:
Q2 showed 18% revenue growth to $16.5 million, recurring revenue up 20% to $13.7 million, 24.1% U.S. procedure share, and adjusted EBITDA of $3.6 million. The core ALLY utilization story is encouraging, but profitability was helped by a $1.1 million tariff refund, cash fell to $13.6 million, operating cash flow was essentially breakeven, and management expects opex to rise as commercial investment resumes.
- Ally Adoption
- Recurring Revenue
- Procedure Volume
- Gross Margin
- Cash Flow
- Europe Expansion
Near term
Q3 procedure volumes face acknowledged seasonal pressure from summer vacations and regional holidays, while new installations typically require 60–90 days to reach full productivity.
The 13-system ALLY backlog provides some placement visibility, but management said the U.S. backlog includes facilities delayed by construction and did not provide a detailed delivery schedule.
Reported gross margin of 59% overstates underlying performance; excluding the tariff refund, adjusted gross margin was 52%. Management characterized the low-50s level as sustainable as recurring revenue grows.
Operating expenses are expected to trend modestly higher toward historical levels, creating near-term variability in EBITDA and earnings.
ESCRS is the first direct European conference presence and could provide evidence of whether international distributor momentum is genuinely recovering, but management described the process as taking several quarters.
Longer term
The investment case is increasingly tied to recurring revenue: it represented 83% of quarterly revenue, while procedure revenue grew 23% year over year and the installed base expanded to 445 systems.
ALLY reached approximately 215 systems, up 30% year over year and nearly half of the total fleet, supporting a potential mix shift toward the newer platform and higher-margin recurring revenue.
U.S. procedure market share rose to 24.1% from 21.4% a year ago, but the call did not independently quantify how much of the gain reflects durable product differentiation versus installed-base expansion and utilization efforts.
The company remains dependent on converting installations—particularly femto-naive customers—into sustained procedure volume; management acknowledged that these accounts ramp more slowly and that legacy-system replacements can temporarily complicate revenue modeling.
Red flags
The strongest adjusted EBITDA quarter included a material $1.1 million tariff refund, so the reported $3.6 million result is not a clean run-rate measure.
Cash declined from $18 million at year-end 2025 to $13.6 million, and positive adjusted EBITDA was offset by inventory and working-capital investment; inventory stood at $24.9 million.
Management offered no formal revenue, margin, EBITDA, or EPS guidance, leaving investors to assess growth and profitability using qualitative targets while expenses normalize upward.
Management's claims that ALLY demand is 'as strong as ever' and that the technology is differentiated were not supported with quantified win rates, customer retention, pricing data, or competitive displacement evidence.
International recovery remains unproven: distributor reengagement was described as a 'work in progress,' with visibility limited by the distributor network.
OpenFilings analyst view from primary-source filings and earnings calls — not investment advice.
From latest 10-K · 2026-03-31
- Operating Cf Burn
- Net Margin Sharply Negative
- Cash Conversion Weak
- Cash Runway Low
Red flags
- Operating Cf Burn — Negative operating cash flow
- Net Margin Sharply Negative — Net margin -58.7%
- Cash Conversion Weak — Cash conversion (CFO/Rev) -25.4%
- Cash Runway Low — Cash runway ~0.9 years
Upcoming earnings
Earnings transcripts
Press & signals
- GlobeNewswire
LENSAR® Reports Second Quarter 2026 Results and Provides Business Update